Yasuo Ishida, MD | |
102 Progress Pkwy # A, Sullivan, MO 63080-2359 | |
(573) 468-6011 | |
(573) 468-7868 |
Full Name | Yasuo Ishida |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 102 Progress Pkwy # A, Sullivan, Missouri |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1811973944 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207V00000X | Obstetrics & Gynecology | 33207 (Missouri) | Primary |
207Q00000X | Family Medicine | 33207 (Missouri) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Yasuo Ishida, MD 6744 Clayton Rd, Saint Louis, MO 63117-1637 Ph: (314) 645-6100 | Yasuo Ishida, MD 102 Progress Pkwy # A, Sullivan, MO 63080-2359 Ph: (573) 468-6011 |
News Archive
Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.
Bibby Scientific Ltd announced today that Stuart®, a leading UK manufacturer of laboratory benchtop equipment, has launched a new range of Undergrad hotplate stirrer kits that offer excellent value for money for a broad range of life science heating and stirring applications.
ImmunoGen, Inc., a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its IMGN901 compound when used for the treatment of Merkel cell carcinoma (MCC). Through a separate process, the European Union (EU) Committee for Orphan Medicinal Products (COMP) concurrently also granted IMGN901 orphan medicinal product designation for the treatment of MCC.
Researchers at Huntsman Cancer Institute (HCI) believe they may be one step closer to understanding how certain forms of colon cancer develop.
Parents who have low health literacy are less likely to choose government-recommended weight-loss strategies, such as increasing physical activity or serving more fruits and vegetables, to help their children control their weight than parents who are better able to understand basic health-related information, a new study suggests.
› Verified 8 days ago
Dr. Roger J. Rembecki, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 965 Mattox Dr, Sullivan, MO 63080 Phone: 573-860-6000 Fax: 573-860-6016 |